CHOP's Bioengineered Cartilage Offers New Hope for Infant Airway Repair

PHILADELPHIA, PA – June 17, 2026 – In a significant leap forward for pediatric medicine, scientists at Children's Hospital of Philadelphia (CHOP) have developed a personalized, bioengineered cartilage graft that promises to revolutionize the treatment for thousands of infants born with a life-threatening airway obstruction. The breakthrough, detailed today in the journal Nature Communications, offers a faster, safer, and more effective alternative to the current grueling surgical standard, potentially sparing the hospital's smallest patients from repeated invasive procedures and long-term complications.

This innovation targets severe subglottic stenosis, a dangerous narrowing of the windpipe just below the vocal cords that affects an estimated 20,000 infants each year. By leveraging a novel tissue engineering method, the Philadelphia-based research team has created a living, patient-specific implant that could fundamentally alter the timeline and outcomes for these vulnerable children.

The Agonizing Wait for Breath

For an infant with severe subglottic stenosis, every breath can be a struggle. The condition, whether congenital or acquired from prolonged intubation in premature babies, can be life-threatening. The standard surgical fix, known as laryngotracheal reconstruction (LTR), is a complex open-airway procedure that involves enlarging the narrowed passage with a piece of cartilage. For decades, surgeons have harvested this cartilage from the patient's own rib cage.

While LTR has saved countless lives, the procedure is fraught with challenges, particularly for the youngest and smallest patients. Many infants simply lack enough costal cartilage—the tissue connecting ribs to the sternum—to create a suitably sized graft. This forces a painful delay. The surgery is postponed, sometimes for years, until the child grows bigger. In the interim, the infant must live with a tracheostomy tube, a surgically inserted device in the neck to enable breathing, which carries its own risks of infection and complication, profoundly affecting quality of life for the child and their family. Furthermore, the act of harvesting rib cartilage creates a second surgical site, increasing pain, recovery time, and the potential for donor site morbidity, such as chest wall deformities. Even when the procedure is successful, the airway is at risk of narrowing again, often necessitating follow-up surgeries.

"We needed something that could be equivalent to a piece of cartilage, integrate well with the surrounding tissue, be well tolerated by the patient, behave like native tissues and regrow and be part of the airway," said Riccardo Gottardi, PhD, a lead researcher on the project, Assistant Professor with the Perelman School of Medicine at the University of Pennsylvania, and head of the Bioengineering and Biomaterials (Bio2) lab. "This required quite a bit of creative thinking because of the additional challenges in children who are so small and still growing."

The Science of a Custom-Built Airway

The solution born from that creative thinking is a first-of-its-kind scaffold technology dubbed MEND, for MENiscus Decellularization. The team, led by Dr. Gottardi and former lab member Paul Gehret, PhD, discovered that meniscal cartilage—the tough, rubbery tissue in the knee—could be transformed into an ideal biological scaffold. By chemically "digesting" away the native cells, elastin, and blood vessels, they created a clean, non-immunogenic collagen structure. This decellularized matrix serves as a blank slate, ready to be repopulated with new, patient-specific cells.

The genius of the approach lies in where those new cells come from. Instead of a major surgery, the team harvests a small number of cartilage progenitor cells (eCPCs) from the patient's ear through a minimally invasive biopsy. These progenitor cells are uniquely suited for the task; they are programmed to mature into cartilage-producing chondrocytes and have demonstrated robust growth and resistance to calcification, a common failure point in other engineered tissues.

This "recellularized" graft is then grown in the lab, becoming a living, personalized implant. The most critical advantage of this technique is speed. While conventional tissue engineering can take up to six months to produce a viable cartilage graft—a timeframe far too long for an infant in respiratory distress—the MEND process can deliver a custom, implant-ready graft in just three to four weeks. This compressed timeline aligns perfectly with the clinical window of one to two months that surgeons often have to intervene effectively.

In preclinical models, the MEND graft not only worked but demonstrated superior performance compared to the standard-of-care costal cartilage, integrating seamlessly with surrounding tissue without any adverse events.

A Legacy of Innovation in Action

This breakthrough is not an isolated event but the latest chapter in CHOP's 171-year history as a global leader in pediatric medicine. It exemplifies the power of the institution's model, where deep clinical expertise converges with pioneering research. The project is a direct result of the collaboration between the clinical and scientific worlds, pairing Dr. Gottardi's bioengineering prowess at the University of Pennsylvania with the on-the-ground clinical needs identified by Ian Jacobs, MD, Medical Director of CHOP's renowned Center for Pediatric Airway Disorders.

This collaborative ecosystem, supported by a network of funding from the National Institutes of Health, the National Science Foundation, and CHOP's own Frontier Program, creates an environment where complex, real-world problems can be met with cutting-edge scientific solutions. The Center for Pediatric Airway Disorders itself represents a comprehensive "aerodigestive" approach, uniting specialists from ENT, pulmonology, and other fields to treat the whole patient.

"This research shows really promising data that suggests this novel approach could overcome the autograft-associated limitations we sometimes encounter when attempting laryngotracheal reconstruction in infants," said Dr. Jacobs. "With more research, we expect this could decrease the need for invasive surgery."

Beyond the Trachea: A Platform for Regeneration

The implications of the MEND technology extend far beyond subglottic stenosis. Dr. Jacobs noted that the team hopes to "apply the technology to other conditions that require a cartilage graft," signaling that this innovation is not a single product but a versatile platform. This is the "early innings" of a new era in regenerative medicine.

Dr. Gottardi's Bio2 lab is already exploring this potential, with active research into using similar decellularized scaffolds for tympanic membrane (eardrum) repair and creating osteochondral grafts for joint cartilage regeneration. The core principles—creating a clean scaffold and repopulating it with a patient's own easily harvested cells—could be adapted to a wide range of reconstructive and orthopedic challenges in both children and adults.

Before the MEND graft can be used in patients, it will undergo further validation to meet rigorous safety and efficacy standards. However, the path forward is clear. This research lays the foundation for a future where a life-threatening diagnosis for an infant can be met not with a series of painful surgeries and years of uncertainty, but with a personalized, living implant grown in a lab, delivered in weeks, and designed to last a lifetime.